Preview

Медицинский Совет

Расширенный поиск

Консервативная лекарственная терапия пациентов с резистентной артериальной гипертензией – время компромисса

https://doi.org/10.21518/2079-701X-2013-9-17-25

Полный текст:

Аннотация

При лечении заболеваний сердечно-сосудистой системы остро стоит проблема сохранения высокого артериального давления даже при проведении адекватной терапии. В настоящем обзоре рассматриваются особенности терапии артериальной гипертензии, резистентной к обычному лечению. Рассмотрены основные подходы к терапии. Уделено внимание классам препаратов, применяемых при этом заболевании, их основным эффектам и особенностям их применения в составе комбинированной терапии, а также новым ЛС.

Об авторе

А. О. Конради
Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова
Россия


Список литературы

1. Диагностика и лечение артериальной гипертензии (Рекомендации 10. Сalhoun D. A., Jones D., Textor S, et al. Resistant Hypertension: Diagnosis, Российского медицинского общества по артериальной гипертонии и Evaluation, and Treatment. A Scientific Statement From the American Heart Всероссийского научного общества кардиологов) // Системные Association Professional Education Committee of the Council for High гипертензии. – 2010. - № 3. – С. 5-27. Blood Pressure Research // Circulation.- 2008. -; Vol. 117. – P. e510-e526

2. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the 11. ADVANCE Collaborative Group. Effects of fixed combination of perindomanagement of arterial hypertension: The Task Force for the management pril and indapamide on macrovascular and microvascular outcomes in of arterial hypertension of the European Society of Hypertension (ESH) patients with type 2 diabetes mellitus (the ADVANCE trial) // Lancet. – and European Society of Cardiology (ESC) // J. Hypertens. – 2007. – Vol. 2007. – Vol. 370. – P.829-840. 25.- P. 1105-1187.

3. Liu I., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A. The Felodipine

4. Mancia G., Fagard R., Narkiewicz K. et al. 2013 Guidelines for the manage-Event Reduction (FEVER) Study: a randomized long-term placebo conment of arterial hypertension: The Task Force for the management of arterial trolled trial in Chinese hypertensive patients // J.Hypertens. – 2005. – hypertension of the European Society of Hypertension (ESH) and European Vol. 23. – P.2157-2172. Society of Cardiology (ESC) // J. Hypertens. – 2013. – Vol. 31.- P. 1281-1357.

5. Jamerson K., Weber M.A., Bakris G.L. Dahlof B., Pitt B., Shi V. et al.

6. Persell S.D. Prevalence of resistant hypertension in United States, 2003 – Benazepril plus amlodipine or hydrochlorothiazide for hypertension in 2008 // Hypertension. – 2011. – Vol. 57. – P. 1076 – 1080. high-risk patients // N. Engl. J. Med. - 2008. – Vol. 359. – P.2417 – 2428.

7. De la Sierra A., Segura J., Banegas J.R., Corostidi M., de la Cruz J.J. Armario 14. Gifford R., Tarazi R. Resistant hypertension: diagnosis and management //

8. P. et al. Clinical features of 8295 patients with resistant hypertension clas-Ann. Intern. Med. - 1978. – Vol. 88. – P. 661–665. sified on the basis of ambulatory blood pressure monitoring //

9. Ramsey L.E., Silas J.E., Freestone S. Diuretic treatment of resistant hyper-Hypertension – 2011. – Vol.57. – P. 171-174. tension // Br. Med. J. – 1980. – Vol. 281. – P. 1101-1103.

10. Daugherty S.L., Powers J.D., Magid D.J., Tavel H.M. et al. Incidence and 16. Graves G.W., Bloomfield R.L., Bukalew V.M. Jr. Plasma volume in resistant prognosis of resistant hypertension in hypertensive patients // Circulation. hypertension: guide to pathophysiology and therapy // Am. J. Med. Sci. –– 2012. – Vol. 125. – P. 1635-1642.1989. – Vol. 298. – P. 361-365.

11. Fagard R.H. Resistant hypertension // Heart. – 2012. – Vol. 98. – P. 254-261.

12. Taler S.J., Textor S.C., Augustine J.E. Resistant hypertension: comparing

13. Esler M., Krum H., Schlaich M.Renal Sympathetic Denervation for hemodynamic management to specialist care // Hypertension. - 2002. – Treatment of Drug-Resistant Hypertension. One-Year Results From the Vol. 39. – P. 982-988. Symplicity HTN-2 Randomized, Controlled Trial // Circulation. – 2012. –

14. Materson B.J., Reda D.J., Cushman W.C., Henderson W.G. Results of combina-Vol. 126. – P. 2976 – 2982.

15. Lohmeier T.E., Iliescu R. Chronic Lowering of Blood Pressure by Carotid Department of Veterans Affairs Cooperative Study Group on Baroreflex Activation. Mechanisms and Potential for Hypertension Antihypertensive Agents // J. Hum. Hypertens. – 1995. – Vol. 9. – P. 791–796. Therapy // Hypertension. – 2011. – Vol. 57. – P. 882 - 886.

16. Сalhoun D. A., Jones D., Textor S, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment. A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research // Circulation.- 2008. -; Vol. 117. – P. e510-e526

17. ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial) // Lancet. – 2007. – Vol. 370. – P.829-840.

18. Liu I., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo controlled trial in Chinese hypertensive patients // J.Hypertens. – 2005. – Vol. 23. – P.2157-2172.

19. Jamerson K., Weber M.A., Bakris G.L. Dahlof B., Pitt B., Shi V. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. - 2008. – Vol. 359. – P.2417 – 2428.

20. Gifford R., Tarazi R. Resistant hypertension: diagnosis and management // Ann. Intern. Med. - 1978. – Vol. 88. – P. 661–665.

21. Ramsey L.E., Silas J.E., Freestone S. Diuretic treatment of resistant hypertension // Br. Med. J. – 1980. – Vol. 281. – P. 1101-1103.

22. Graves G.W., Bloomfield R.L., Bukalew V.M. Jr. Plasma volume in resistant hypertension: guide to pathophysiology and therapy // Am. J. Med. Sci. – 1989. – Vol. 298. – P. 361-365.

23. Taler S.J., Textor S.C., Augustine J.E. Resistant hypertension: comparing hemodynamic management to specialist care // Hypertension. - 2002. – Vol. 39. – P. 982-988.

24. Materson B.J., Reda D.J., Cushman W.C., Henderson W.G. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents // J. Hum. Hypertens. – 1995. – Vol. 9. – P. 791–796.

25. Moser M. Suppositions and speculations—their possible effects on treatment decisions in the management of hypertension // Am. Heart. J. – 1989. – Vol. 118(6). – P. 1362-1369.

26. McInnes G.T., Yeo W.W., Ramsay L.E., Moser M. Cardiotoxicity and diuretics: much speculation, little substance // J. Hypertens.- 1992. – Vol. 10(4). – P. 317-335.

27. Freis E.D. The efficacy and safety of diuretics in treating hypertension // Ann. Intern. Med. – 1995. – Vol. 122(3). – P.223 - 226.

28. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP) // JAMA. – 1991. – Vol. 265(24). – P. 3255 – 3264.

29. Cushman W.C., Ford C.E., Cutler J.A. et al., for the ALLHAT Collaboratyive Research Group. Success and predictors of blood pressure control in diverse North American Settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT) // J. Clin. Hypertens. – 2002. – Vol. 4. – P. 393–404.

30. Чазова И.Е., Мартынюк Т.В., Небиеридзе Д.В. и соавт. Сравнительная эффективность лечения фиксированными комбинациями различных доз рамиприла и гидрохлоротиазида // Кардиоваскулярная терапия и профилактика. - 2010. – Т. 9. - №4. – С. 25-31.

31. Moser M. Setaro J. Resistant or Difficult-to-Control Hypertension // N. Engl. J. Med. – 2006. – Vol. 355. – P. 385 - 392.

32. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Hyperaldosteronism among black and white subjects with resistant hypertension // Hypertension.- 2002. – Vol. 40. – P. 892-896.

33. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension // Am. J. Hypertens. – 2003. – Vol. 16. – P. 925 – 930.

34. Parthasarathy K.H., Alhashmi K., McMahon A.D. Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study // BMC Cardiovascular Disorders. – 2007. – Vol. 7. – P.14.

35. Chapman N., Dobson J., Wilson S., Dahlof B., Sever P.S., Wedel H., Poulter N.R. Effect of spironolactone on blood pressure in subjects with resistant hypertension // Hypertension. – 2007. – Vol. 49. – P. 839 – 845.

36. de Souza F., Muxfeldt E., Fiszman R., Salles G. Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension // Hypertension. – 2010. – Vol. 55. – P. 147-152.

37. Sharabi Y., Adler E., Shamis A., Nussinovitch N., Markovitz A., Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension // Am. J. Hypertens. – 2006. – Vol. 19. – P. 750 – 755.

38. Lane D.A., Shah S., Beevers D.G. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. // J. Hypertens. – 2007. – Vol. 25. – P. 891 – 894.

39. Václavík J. Sedlák R., Plachý M. et al. Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT) A Randomized, Double-Blind, Placebo-Controlled Trial // Hypertension. – 2011. – Vol. 57. – P. 1069 – 1075.

40. Saha C., Eckert G.J., Ambrosius W.T., Chun T.Y., Wagner M.A., Zhao Q., Pratt J.H. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension // Hypertension. – 2005. – Vol. 46. – P. 481 – 487.

41. Staessen J.A., Fagard R., Thijs L. et al., for the Systolic Hypertension in Europe Trial Investigators. Randomised double–blind comparison of placebo and active treatment for older patients with isolated systolic hypertension // Lancet. – 1997. – Vol. 350. – P. 757 – 764.

42. Liu L., Wang J.L., Gong L., Liu G., Staessen J.A. For the Syst-China Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension // J. Hypertens. – 1998. – Vol. 16. – P. 1823-1829.

43. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Principal results of Hyretension Optimal Treatment (HOT) randomized trial // Lancet. – 1998. – Vol. 351. – P. 1755-1762.

44. Dahlof B., Sever P.S., Poulter N.R., et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // Lancet. – 2005. – Vol. 366. – P. 895-906.

45. Poulter N. R. A new dimension in hypertension management with the amlodipine/perindopril combination // J. of Hypertens. – 2011. – Vol. 29. – P. S15 - S21.

46. Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomised to double–blind treatment with a long–acting calcium channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) // Lancet. – 2000. – Vol. 356. – P. 366 – 372.

47. Kolloch R.E. INVEST: Results of combined strategies to control blood pressure // Clin. Cardiol. – 2001. – Vol. 24, Suppl. V. - V12–V13.

48. Sica D.A. Drug Combination in the Treatment of Hypertension Never-ending Novelty // Hypertension. – 2010. – Vol. 56. – P. 22 – 23.

49. Staessen J., Carter B.L., Btown T.E., Elliot W.J., Black J.H. Comparison of nifedipine alone and with diltiazem and verapamil in hypertension. // Hypertension. – 1996. – Vol. 28. – P. 109-114.

50. Hall J.E., Guyton A.C., Smith M.J. Jr, Coleman T.G. Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin // Am. J. Physiol. – 1980. –Vol. 239. - F271–F280.

51. Hall J.E. Control of sodium excretion by angiotensin: intrarenal mechanisms and blood pressure regulation // Am. J. Physiol. – 1986. – Vol. 250. - R960 – R972.

52. Hall J.E., Brands M.W., Shek E.W. Central role of the kidney and abnormal fluid volume control in hypertension // J. Hum. Hypertens. – 1996. – Vol. 10. – P. 633–639.

53. Hall J.E., Crook E.D., Jones D.W., Wofford M.R., Dubbert P.M. Mechanisms of obesity-associated cardiovascular and renal disease // Am. J. Med. Sci. – 2002. – Vol. 324. – P. 127 – 137.

54. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145—153.

55. Lonn E.M., Yusuf S., Dzavik V., Doris C.I., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W.A., Teo K.K. Effects of Ramipril and Vitamin E on Atherosclerosis The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) // Circulation. – 2001. – Vol.103. – P.919-925.

56. Furberg C.D., Psaty B.M. Should Evidence-Based Proof of Drug Efficacy Be Extrapolated to a “Class of Agents”? Circulation 2003;108:2608-2610

57. Sanford M, Keam S.J. Olmesartan modoximil/amlodipine // Drugs.- 2009.- Vol.69.- P. 717-729.

58. Poldermans D., Glazer R., Karagiannis G. et al. Tolerability and blood pressure lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrichlorothiazide in adult patients with stage 2 hypertension // Clin. Ther. – 2007.- Vol. 29.- P. 279–289.

59. Alleman Y., Fraile B., Lambert M. et al. Efficacy of the combination of amlodipine and valsartan in patients uncontrolled with monotherapy: the Exforge in Failure after Single Therapy (Ex-FAST) Study // J. Clin. Hypertens. (Greenwich) 2008. - Vol. 10 (3) - P.185–194.

60. Ferrari P., Marti H.P., Pfister M., Frey F.J. Additive antiproteinuric effect of combined ACE inhibitor and angiotensine II receptor blockade // J.Hypertens. – 2002.- Vol. 20.- P.125-130.

61. Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril or both in patient at high risk fo vascular events // N. Engl. J. Med. – 2008. – Vol. 358. – P. 147-1559.

62. Mann J.F., Schmieder R.F., McQueen M. et al. Renal outcomes with telmisartan, ramipril or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, duble-blind, controlled trial // Lancet. – 2008. – Vol. 372. – P. 547-553.

63. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. LIFE Study Group. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE ): a randomized trial against atenolol //Lancet.- 2002.- Vol.359.- P. 995-1003.

64. Hirsch S. A different approach to resistant hypertension // Cleveland Clinical J. of Med. – 2007. – Vol. 74 (6). – P. 449 – 455.

65. Sarafidis P.,Bakris G.L. Resistant Hypertension. An Overview of Evaluation and Treatment // J. Am. Coll. Cardiol, - 2008. – Vol. 52. – P. 1749 - 1757.

66. Rodilla E., Costa J.A., Perez-Lahiguera F. et al. Spironolactone and doxazosin treatment in patients with resistant hypertension // Rev. Esp. Cardiol. – 2009. – Vol. 62. – P. 158-166.

67. Elliott W.J. Management of Resistant hypertension // Curr.Cardiovasc.Rep. – 2011. – Vol. 5. – P. 373-382.

68. Ланг Г.Ф. Гипертоническая болезнь. Москва. Медгиз. 1950

69. Van Zwieten P.A., Thoolen M.J., Timmermanns P.B. The hypotensive activity and side effects of methyldopa, clonidine and guanfacine // Hypertension. – 1984. – Vol.6 – Suppl. II. – P. 28-33.

70. Ernsberger P., Westbrooks K.L., Christen M.O., Schaefer S.G. A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors // J. Cardiovasc. Pharmacol. – 1992. – Vol. 20. – Suppl. 4. – P. S1-S10.

71. Frei M., Kuster L., Gardosch-von Klosigk P.- P. et al. Moxonidine and hydrochlorthiazide in combination: a synergic antihypertensive effect // J. Cardiovasc. Pharmacol. – 1994. – Vol. 24. – Suppl. 1. – P. S25-S26.

72. Kuppers H., Jager B., Luszick J. et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension // J. Hypertens. – 1997. – Vol. 17. - P. 93-97.

73. Benedict C.R. Centrally acting antihypertensive drugs: re-emergence of sympathetic inhibition in the treatment of hypertension // Curr. Hypertens. Rep. – 1999. – Vol. 4. – P. 305-312.

74. Oliver J.J., Dear J.W, Webb D.J. Clinical Potential of Combined Organic Nitrate and Phosphodiesterase Type 5 Inhibitor in Treatment-Resistant Hypertension // Hypertension. – 2010. – Vol. 56. – P. 62-67.

75. Stokes G.S., Bune A.J., Huon N., Barin E.S. Long-term effectiveness of extended-release nitrate for the treatment of systolic hypertension // Hypertension. – 2005. – Vol. 45. - N3. – P.:380 - 384

76. Saito Y., Nakao K., Mukoyama M., Imura H. Increased plasma endothelin level in patients with essential hypertension // N.Engl. J. Med. – 1990. – Vol. 322. – N. 3. – P. 205.

77. Krum H., Viskoper R.J., Lacourciere Y. et al. The effect of the endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators // N.Engl. J.Med. – 1998. – Vol. 338. – N. 12. – P. 784-790.

78. Enseleit F., Luscher T.F., Ruschitzka F. Darusentan: a new perspective for treatment of resistant hypertension // Expert Opin. Investig. Drugs. – 2008. – Vol. 17. – N. 8. – P. 1255-1263.

79. Bakris G.L., Lindholm L.H., Black H.R., Krum H., Linas S., Linseman J.V., Arteburn S., Sager P., Weber M. Divergent results using clinic and ambulatory blood pressures/ Report of a Darusentan-Resistant Trial // Hyprtrnsion. – 2010. – Vol. 56. – P. 824-830.

80. Mann S.J. Drug therapy for resistant hypertension: simplifying the approach // J. Clin. Hypertens. - 2011. – Vol.13. – P.120–130.

81. Egan B.M., Basile J.N., Rehman S.U., Davis P.B., Grob C.H. 3rd, Riehle J.F., Walters C.A., Lackland D.T., Merali C., Sealey J.E., Laragh J.H. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial //Am. J. Hypertens. – 2009. - Vol.22. – N.7. – P. 792 – 801.

82. Furberg C.D. Renin Test-Guided Drug Treatment of Hypertension: The Need For Clinical Trials // Am. J. Hypertens. - 2011. – Vol. 24. – N. 11. – P.1158–1163.


Просмотров: 64


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)